Daniel S. Jaffee
Management
When your first quarter was $88,000, it was very impressive. So I would look at it more as a percentage and see how is it rolling, and clearly it's—we were up 100% from quarter one to quarter two, we were up 60% up to three, we were up another 40% up to four. So the question is where is that going to level out. Our expectations certainly are more than it's going to go up $100,000 a quarter infinitum. I mean, as the snowball rolls, yes, your percentage may come down but the $100,000 will be exceeded. So all I can give you is our initial reaction. Our initial reaction is very positive. The market has received it very well. If you think about it, we launched this product, which is a high-end, high-performance product, in a very tough economy at the same time when there was something called swine flu, which you would think wouldn't impact a product like Calibrin Z, which is particularly targeted for zearalenone and swine. But swine flu, how does that impact it? Well, when the whole country of Egypt goes out and slaughters their entire swine population, you can see the people took hysterical reactions to the whole concept of swine flu. So we feel very positive. For us to have eclipsed a million dollars in sales in the first year of launch at what we have already communicated at better than average margins, we feel very positive. The team is doing a great job, getting a lot of positive support from our distributor network throughout the globe. I, personally, was out in Asia making calls and it's very impressive how well this product is being received. And so how high is up? Nobody knows. But as you know, because you've followed the pluses and minuses, we never sold this much of Brick Aid or something like that and we were very clear with that communication. This one, in the first twelve months it's looking like a winner.